Abstract
A substantial proportion of patients who undergo cardiac rhythm device implantation receive anticoagulation to prevent thromboembolism. Many patients have coexisting cardiovascular diseases treated with antiplatelet therapy. Anticoagulation may increase the risk of hemorrhagic complication, while withdrawal of anticoagulation may increase thromboembolic risk. In this article, we review and describe the available evidence, in order to inform best practice .
MeSH terms
-
Anticoagulants / administration & dosage*
-
Anticoagulants / adverse effects*
-
Blood Loss, Surgical / prevention & control
-
Defibrillators, Implantable*
-
Evidence-Based Medicine
-
Humans
-
Pacemaker, Artificial
-
Perioperative Care
-
Platelet Aggregation Inhibitors / administration & dosage*
-
Platelet Aggregation Inhibitors / adverse effects*
-
Postoperative Hemorrhage / epidemiology
-
Postoperative Hemorrhage / prevention & control
-
Practice Guidelines as Topic*
-
Thromboembolism / epidemiology
-
Thromboembolism / prevention & control
Substances
-
Anticoagulants
-
Platelet Aggregation Inhibitors